Tag:

weight loss

Health

Novo Nordisk Price Cuts: Will Ozempic, Wegovy Be More Accessible?

by Chief Editor
written by Chief Editor

Novo Nordisk’s Price Cuts: A Turning Point for GLP-1 Medications?

Novo Nordisk’s announcement of significant price reductions for its blockbuster GLP-1 medications – Ozempic, Rybelsus and Wegovy – has sent ripples through the healthcare industry. The move, slated to take effect January 1, 2027, will lower the list price of each drug to $675 per month. But what does this mean for patients, insurers, and the future of these increasingly popular treatments?

The Impact on Patients with Insurance

The price cuts are specifically designed to benefit insured patients, particularly those with high-deductible health plans or coinsurance. These individuals often pay a percentage of the list price, so a lower list price directly translates to lower out-of-pocket costs. Novo Nordisk’s Jamey Millar explained that the company anticipates improvements in access and uptake within the commercial insurance market.

Currently, Wegovy and its pill counterpart have list prices around $1,350 per month, while Ozempic and Rybelsus are priced around $1,027. The 35% to 50% reduction represents substantial savings for those directly impacted by list prices.

Why Now? Competition and Market Dynamics

Novo Nordisk’s decision isn’t solely altruistic. The company faces growing competition from Eli Lilly, whose obesity drug, Zepbound, is gaining market share. Recent study results similarly indicated that Novo Nordisk’s next-generation obesity drug, CagriSema, didn’t demonstrate weight loss superior to Zepbound. This competitive pressure likely played a role in the pricing strategy.

The pharmaceutical market is complex. While list prices are important, what truly matters to employers and insurers are “net prices” – the actual cost after rebates and discounts. Novo Nordisk’s move aims to address affordability for a specific segment of the insured population, potentially bolstering its position against rivals.

Cash-Paying Customers and Previous Price Drops

It’s important to note that these modern price cuts don’t affect cash-paying customers in the same way. Novo Nordisk previously reduced prices for injectable Wegovy and most Ozempic dosages to $349 a month for direct purchases through the company, telehealth partners, or retail pharmacies. Lilly has also implemented similar price reductions for direct purchasers of Zepbound.

The Broader Trend of GLP-1 Accessibility

The increasing availability and now, decreasing prices, of GLP-1 medications signal a potential shift in the treatment of obesity and type 2 diabetes. These drugs have demonstrated significant clinical benefits, but their high cost has historically been a barrier to access. This price reduction could open the door for more widespread adoption, potentially impacting public health outcomes.

Did you recognize? GLP-1 medications were originally developed to treat type 2 diabetes, but their weight loss effects have led to their increasing use for obesity management.

Future Outlook: What to Expect

The long-term effects of Novo Nordisk’s price cuts remain to be seen. It’s likely that other pharmaceutical companies will respond with their own pricing strategies. The focus will likely remain on navigating the complex landscape of insurance coverage and net pricing. The competition between Novo Nordisk and Eli Lilly will continue to drive innovation and potentially further affordability improvements.

Pro Tip: If you are considering a GLP-1 medication, discuss your insurance coverage and potential out-of-pocket costs with your healthcare provider and insurance company.

FAQ

Q: When will the new prices take effect?
A: The price reductions will begin on January 1, 2027.

Q: Which medications are included in the price cuts?
A: Ozempic, Rybelsus, and Wegovy will all have a new list price of $675 per month.

Q: Will these price cuts affect everyone?
A: The primary benefit is intended for insured patients with high-deductible plans or coinsurance.

Q: Does this mean my insurance will automatically cover these drugs?
A: Not necessarily. Insurance coverage decisions are separate from list prices and depend on various factors.

Do you have questions about GLP-1 medications or their impact on your health? Share your thoughts in the comments below!

Explore more articles on healthcare affordability and diabetes management on our website.

0 comments
0 FacebookTwitterPinterestEmail
Health

Fitness trainer with 18 years of experience shares the most sustainable weight loss hack: ‘You need to eat more…’

by Chief Editor
written by Chief Editor

The “Eat More” Diet: Why Volume and Nutrient Density Are the Future of Weight Loss

For decades, the weight loss narrative has centered around restriction. But a growing chorus of fitness professionals, including Chennai-based trainer Raj Ganpath, are flipping the script. The key to sustainable weight loss isn’t necessarily eating less, but eating smarter. This approach focuses on maximizing volume and nutrient density, effectively managing hunger without the deprivation often associated with traditional calorie-deficit diets.

The Hunger Hurdle: Why Calorie Restriction Fails

The biggest challenge with simply cutting calories is, unsurprisingly, hunger. As Raj Ganpath points out, while initial calorie reductions might yield short-term results, the constant gnawing sensation often leads to abandonment of the plan. This isn’t a lack of willpower; it’s a biological response. The body resists prolonged periods of deprivation.

The Power of Volume: Filling Up Without Filling Out

The core of this novel approach lies in understanding the concept of volume. By prioritizing foods that are low in calorie density – meaning they offer a large portion size for a relatively compact number of calories – individuals can feel fuller for longer. This naturally leads to reduced overall calorie intake without the feeling of being constantly hungry.

Nutrient Density: Fueling Your Body, Not Just Filling It

Volume alone isn’t enough. The foods chosen must also be nutrient-dense. This means focusing on foods packed with vitamins, minerals, and fiber. Prioritizing protein is also crucial, as it’s highly satiating and helps preserve muscle mass during weight loss. Shifting away from calorie-dense, nutrient-poor options is paramount.

Cooking Methods Matter: The Hidden Calorie Culprit

Beyond food choices, how food is prepared plays a significant role. Traditional cooking methods like frying, even shallow or sautéing, add significant calories through oil. Switching to methods like steaming, pressure cooking, air frying, or baking drastically reduces calorie intake without sacrificing flavor or texture. This simple change can have a substantial impact on overall results.

Beyond the Plate: The Role of Lifestyle

While dietary adjustments are central, sustainable weight loss isn’t solely about food. Factors like sleep, stress management, and regular physical activity all contribute to hormonal balance and metabolic function, influencing appetite and fat loss. A holistic approach is essential for long-term success.

The Future of Weight Loss: Personalized Nutrition and Behavioral Science

The “eat more” approach aligns with emerging trends in nutrition science. Personalized nutrition, tailoring dietary recommendations to individual needs and genetics, is gaining traction. Behavioral science is increasingly being applied to weight loss, recognizing the importance of habit formation and psychological factors. This shift moves away from restrictive diets and towards sustainable lifestyle changes.

Frequently Asked Questions

Q: Does this mean I can eat whatever I want?
No. While you can eat larger portions, the focus is on choosing foods that are low in calorie density and high in nutrients.

Q: Is this approach suitable for everyone?
It’s generally a safe and effective approach for most people, but it’s always best to consult with a healthcare professional or registered dietitian before making significant dietary changes.

Q: What are some examples of high-volume, nutrient-dense foods?
Vegetables (especially leafy greens), fruits, lean proteins, and whole grains are excellent choices.

Pro Tip

Experiment with adding more vegetables to your meals. They add bulk, fiber, and nutrients without significantly increasing calorie intake. Try adding spinach to your omelets, or a side salad to your lunch.

Ready to ditch the diet and embrace a more sustainable approach to weight loss? Explore more articles on mindful eating and healthy habits on our site. Share your experiences and questions in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush

by Chief Editor
written by Chief Editor

The Shifting Sands of the GLP-1 Market: Why Eli Lilly is Surging Ahead

For years, Novo Nordisk’s Ozempic and Wegovy dominated conversations around GLP-1 drugs – a class of medications initially designed for type 2 diabetes, but quickly gaining traction for weight loss. However, the landscape is changing. While Novo Nordisk was the first to market with a GLP-1 drug in 2017, another player has recently taken the lead in this lucrative market.

From Diabetes Treatment to Weight Loss Gold Rush

GLP-1 drugs work by interacting with hormonal pathways involved in digestion, helping to regulate blood sugar and control appetite. Novo Nordisk’s semaglutide is available as Ozempic for type 2 diabetes and Wegovy for obesity. These drugs have shown promise in managing not only diabetes but also conditions like heart disease and potentially even Alzheimer’s disease.

Eli Lilly’s Ascent with Mounjaro and Zepbound

Eli Lilly (NYSE: LLY) is the company making significant inroads. Their drugs, tirzepatide marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, entered the market later than Novo’s offerings but have quickly gained market share. Currently, Lilly holds 60% of the U.S. Market, while Novo Nordisk’s share has decreased to 39%.

Recent financial reports demonstrate this shift. Lilly reported triple-digit revenue growth for both Mounjaro and Zepbound, collectively generating over $11 billion in revenue in the recent quarter.

Manufacturing and Clinical Trial Success: Key to Lilly’s Growth

A crucial factor in Lilly’s success has been its ability to ramp up manufacturing, ensuring consistent availability of its products. Both semaglutide and tirzepatide experienced shortages in the past, highlighting the importance of reliable supply chains.

a head-to-head study comparing Zepbound and Wegovy revealed that Zepbound facilitated greater weight loss in patients, potentially influencing both patient and physician preferences.

The Pill Factor: A New Convenience

Novo Nordisk recently launched a Wegovy pill, offering a more convenient alternative to injectables. However, Eli Lilly is also developing an oral weight loss candidate currently under regulatory review. Unlike the Wegovy pill, Lilly’s oral option doesn’t require dietary restrictions, potentially making it a more appealing and hassle-free choice for patients.

Potential for Alzheimer’s Treatment Remains

Beyond weight loss and diabetes, research continues to explore the potential of GLP-1 drugs in treating other conditions. Novo Nordisk still believes GLP-1 drugs could be a promising treatment for Alzheimer’s disease, despite recent trial setbacks with similar drugs.

Frequently Asked Questions

What are GLP-1 drugs? GLP-1 drugs are medications that interact with hormonal pathways to regulate blood sugar and appetite, initially developed for type 2 diabetes but also used for weight loss.

What is the difference between Ozempic and Wegovy? Both contain semaglutide, but Ozempic is approved for type 2 diabetes, while Wegovy is approved for obesity.

What is tirzepatide? Tirzepatide is the active ingredient in Eli Lilly’s Mounjaro (for type 2 diabetes) and Zepbound (for weight loss).

Are there any side effects associated with GLP-1 drugs? Lawsuits allege serious side effects, including vision loss, brain dysfunction, and gastrointestinal issues. It’s important to discuss potential risks with a healthcare professional.

Could GLP-1 drugs be used to treat other conditions? Research suggests potential benefits in treating conditions like heart disease, kidney disease, drug addiction, and Alzheimer’s disease.

Pro Tip: Always consult with your doctor before starting any new medication, including GLP-1 drugs, to discuss potential benefits and risks.

Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

Explore more articles on pharmaceutical investments and emerging healthcare trends to stay informed about the latest developments in the industry.

0 comments
0 FacebookTwitterPinterestEmail
Health

The View ’s Joy Behar Reveals How Much Weight She’s Lost Using a GLP-1

by Chief Editor
written by Chief Editor

The GLP-1 Revolution: How Weight Loss Drugs Are Changing the Celebrity Landscape – and Beyond

A growing number of celebrities are openly discussing their experiences with GLP-1 medications, sparking a wider conversation about weight loss, body image and the future of health. From television personalities like Joy Behar to acclaimed actresses like Kate Winslet, the utilize of drugs like Ozempic and Mounjaro is becoming increasingly prevalent, raising questions about accessibility, ethics, and long-term effects.

The View From the Top: Celebrities Share Their Journeys

Joy Behar, co-host of The View, recently revealed she lost over 20 pounds using a GLP-1 drug, noting that she wasn’t alone in her experience. Several of her co-hosts, including Savannah Chrisley and Whoopi Goldberg, have also utilized the medication for weight loss. Goldberg shared she was almost 300 pounds before starting the medication.

The trend extends beyond daytime television. Lizzo admitted to trying the medications, even as Real Housewives of New Jersey star Jennifer Aydin openly discussed her success with Mounjaro. Even those initially hesitant, like Kate Winslet, have weighed in, expressing concern about the trend but acknowledging its growing popularity.

Beyond Ozempic: A Growing Family of Medications

While Ozempic has become synonymous with this new wave of weight loss drugs, several other GLP-1 medications are gaining traction. Mounjaro, used by Jennifer Aydin and others, is also proving effective. These medications work by mimicking a hormone that regulates insulin, leading to increased feelings of fullness and reduced appetite.

The Allure and the Risks: Why Are These Drugs So Popular?

The appeal of GLP-1 medications lies in their effectiveness. Many users report significant weight loss with relatively few side effects, compared to traditional weight loss methods. But, the medications aren’t without potential drawbacks. Some, like model Lottie Moss, experienced negative side effects, while others, like Tracy Morgan, found the medications didn’t work for them.

There are also concerns about accessibility and equitable distribution. These medications are often expensive and may not be covered by insurance, creating a disparity in access. Some worry about the potential for misuse and the impact on individuals with genuine medical needs.

The Future of Weight Management: What’s Next?

The increasing popularity of GLP-1 medications is likely to drive further innovation in the field of weight management. Researchers are exploring new formulations and delivery methods, as well as investigating the long-term effects of these drugs.

The conversation is also shifting towards a more holistic approach to health, with an emphasis on lifestyle changes, such as diet and exercise, alongside medical interventions. As seen with Kandi Burruss, the medications aren’t a guaranteed solution and may not be effective for everyone.

Celebrity Experiences: A Mixed Bag

The experiences of celebrities highlight the diverse outcomes associated with these medications. Brooks Nader stopped taking Ozempic before competing on Dancing With the Stars, while Jonathan Van Ness credits GLP-1s with helping them achieve a healthier lifestyle. Caroline Stanbury found success with Ozempic, while Tori Spelling tried Ozempic and then switched to Mounjaro.

These varied experiences underscore the importance of individual assessment and personalized treatment plans.

Frequently Asked Questions

  • What are GLP-1 medications? These medications mimic a hormone in the body that regulates insulin and appetite, leading to weight loss.
  • Are these drugs safe? While generally considered safe, they can have side effects and may not be suitable for everyone.
  • Do these drugs require a prescription? Yes, GLP-1 medications require a prescription from a healthcare professional.
  • Are these drugs only for weight loss? Originally developed to treat type 2 diabetes, they have also been approved for weight management in certain cases.

Did you know? Several celebrities, including Rosie O’Donnell and Sunny Hostin, have also used GLP-1 medications to aid in their weight loss journeys.

Explore more articles on health and wellness here.

0 comments
0 FacebookTwitterPinterestEmail
Health

How GLP-1 drugs affect the body beyond weight loss and glucose control

by Chief Editor
written by Chief Editor

The Double-Edged Sword: Navigating the Risks of GLP-1 Weight Loss and Diabetes Drugs

The booming popularity of drugs like semaglutide and tirzepatide, initially designed for type 2 diabetes, has surged thanks to their remarkable weight loss effects. But as millions embrace these medications, a clearer picture of their potential side effects and long-term risks is emerging. Recent research, published in the Journal of Clinical Investigation, underscores the necessitate for careful monitoring and a nuanced understanding of these powerful therapies.

Beyond Nausea: A Spectrum of Potential Side Effects

Gastrointestinal issues remain the most common complaint. Studies indicate that up to 19% of patients on GLP-1 receptor agonists (GLP-1RAs) experience nausea and 7.6% report vomiting. However, the concerns extend far beyond digestive discomfort. Researchers are investigating potential links to a range of conditions, from gallbladder problems to more serious neurological and psychiatric effects.

Tirzepatide, a dual GLP-1R and GIP receptor agonist, has demonstrated greater efficacy in weight loss and glucose control than GLP-1RAs alone. However, studies indicate it doesn’t necessarily translate to fewer gastrointestinal side effects. in fact, some data suggest a higher risk of vomiting with tirzepatide.

Pro Tip: Rapid dose escalation of medications like semaglutide can exacerbate side effects. A slower, more gradual approach, guided by a healthcare professional, is often recommended.

Thyroid Cancer Concerns: A Complex Picture

Early concerns about an increased risk of medullary thyroid carcinoma (MTC) stemmed from rodent studies. While GLP-1 receptors aren’t typically found in healthy human thyroid C-cells, they are present in many hyperplastic C-cells and MTCs. Data from France has suggested a possible higher risk of MTC in individuals treated with GLP-1RAs, prompting a contraindication for those with a history of MTC or Multiple Endocrine Neoplasia syndrome type 2.

However, absolute event numbers remain low, and epidemiological findings for other thyroid cancer subtypes are inconsistent. Continued vigilance and pharmacovigilance are crucial.

Neurological and Psychiatric Effects: Emerging Signals

The potential impact on mental health is a growing area of investigation. While obesity and type 2 diabetes themselves are risk factors for depression and suicidal ideation, some studies have linked GLP-1RA use to increased anxiety, suicidal behavior, and major depression. Conversely, other research suggests a possible antidepressant effect.

A retrospective study found a two-fold increased risk of anxiety and suicidal behavior and a three-fold increased risk of major depression among GLP-1RA users. However, the findings are complex and require further investigation, with some meta-analyses showing no association with suicidal ideation.

Ocular Safety: Retinopathy and NAION

Cardiovascular outcomes trials have revealed an increased risk of retinopathy complications with semaglutide, particularly in individuals with pre-existing retinopathy. There’s as well been a signal for non-arteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition, with some studies reporting a doubled risk associated with semaglutide exposure.

The Role of Precision Medicine and Pharmacovigilance

The emerging data highlights the need for a more personalized approach to GLP-1RA therapy. Factors like age, kidney function, pregnancy status, and risk of lean mass loss during rapid weight reduction should all be carefully considered. Improved pharmacovigilance and standardized adverse event reporting are essential to better understand the risk-benefit profiles of these medications.

Researchers emphasize that even common GI adverse effects require comprehensive evaluation. Understanding how these drugs affect diverse populations is paramount.

Frequently Asked Questions

What are GLP-1RAs?
GLP-1RAs are medications that mimic the effects of a natural hormone called glucagon-like peptide-1, used to treat type 2 diabetes and promote weight loss.
What is tirzepatide?
Tirzepatide is a medication that activates both GLP-1 and GIP receptors, often leading to greater weight loss and glucose control than GLP-1RAs alone.
Are GLP-1RAs safe?
GLP-1RAs are generally considered safe, but they can cause side effects, and potential long-term risks are still being investigated.
Should I be concerned about thyroid cancer?
If you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, GLP-1RAs may not be suitable for you. Discuss your risk factors with your doctor.

Disclaimer: This article provides general information and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized guidance.

Explore Further: Read more about GLP-1RA precision medicine in the Journal of Clinical Investigation.

0 comments
0 FacebookTwitterPinterestEmail
Health

How to stop weight-loss drugs ageing you by a decade

by Chief Editor
written by Chief Editor

GLP-1s and Exercise: A New Era of Fitness and Wellbeing

The rise of GLP-1 medications like Wegovy and Mounjaro is reshaping not only approaches to weight loss but similarly how individuals integrate exercise into their lives. These drugs, initially designed to manage type 2 diabetes, are gaining traction for their weight-loss benefits, but maximizing their impact requires a nuanced understanding of how to combine them with physical activity.

Understanding the Fatigue Factor

A common side effect reported by users of GLP-1 medications is fatigue. Research from Second Nature, a weight loss plan assisting users of Mounjaro and Wegovy, found that 44% of people felt more tired than usual after four weeks, decreasing to 22% by week eight. This fatigue typically peaks within 48 to 72 hours of injection and often subsides as the body adjusts to each dose.

The ‘If/Then’ Strategy for Consistent Movement

Nutritionist Robbie Puddick of Second Nature recommends employing an “if/then” approach to fitness. Instead of abandoning workouts altogether when feeling fatigued, individuals can modify their routines. For example, “If I experience too tired for my workout, then I’ll do five minutes of walking instead,” or “If I feel nauseous during exercise, then I’ll switch to some gentle yoga.” This strategy promotes consistency even when faced with side effects.

Shorter, Separated Workouts for Optimal Energy Levels

Fitness experts suggest breaking down exercise into shorter, more manageable chunks. Instead of hour-long sessions, consider 20-minute bursts of activity. Separating strength and cardio workouts can also prevent exhaustion. A brisk walk in the morning followed by a strength session in the evening can be more achievable than a single, lengthy workout.

Cardio Considerations: Low-Impact Options

For those experiencing fatigue or carrying excess weight, low-impact cardio options like elliptical training, cycling, swimming, or dancing are ideal. These activities minimize stress on joints and allow for sustained cardiovascular benefits. Prioritizing enjoyable activities increases adherence.

Hydration and Nutrition: Fueling Your Body on GLP-1s

Staying hydrated is crucial, but sipping water between meals is recommended to avoid a false sense of fullness. A nutrient-dense diet, rich in vitamins, minerals, iron (particularly for women), and fiber, is essential. Fiber can help mitigate constipation, a potential side effect of GLP-1s. Timing food around exercise is also key, with a modest snack before training and protein afterwards to support muscle protein synthesis.

Monitoring Your Health and Knowing When to Seek Medical Advice

Due to reduced caloric intake, individuals may experience dizziness or lightheadedness, potentially due to low blood sugar or blood pressure. Monitoring blood pressure at home and, if applicable, glucose levels (for those on other glucose-lowering drugs) is advisable. It’s crucial to consult a doctor if experiencing chest pain, shortness of breath, palpitations, or joint/muscle pain. Vomiting warrants immediate medical attention, potentially requiring a dose adjustment or discontinuation of the medication.

Strength Training for All Ages

Muscle loss is a significant concern with age, increasing the risk of falls and frailty. Strength training is vital for maintaining muscle mass and overall health. Individuals, like Hooton who achieved a 265lb deadlift at 62, demonstrate that strength training is beneficial at any age.

FAQ

Q: What should I do if I feel too tired to exercise while on a GLP-1 medication?
A: Utilize the “if/then” strategy. For example, if you’re too tired for your usual workout, do a shorter, less intense activity like walking or yoga.

Q: Is it better to do one long workout or several shorter ones?
A: Shorter, more frequent workouts are often more manageable when experiencing fatigue.

Q: What type of cardio is best if I have joint pain?
A: Low-impact options like elliptical training, cycling, or swimming are great choices.

Q: When should I contact my doctor about side effects?
A: Contact your doctor if you experience chest pain, shortness of breath, palpitations, vomiting, or significant joint/muscle pain.

Q: Is strength training safe for older adults?
A: Yes, strength training is highly beneficial for older adults and can help prevent muscle loss and frailty.

Did you understand? Muscle loss accelerates with age, but strength training can help counteract this process and improve overall health.

Pro Tip: Listen to your body. Don’t push yourself too hard, especially when starting a new exercise routine or adjusting to a GLP-1 medication.

Explore more articles on healthy living and weight management on our website. Subscribe to our newsletter for the latest updates and expert advice.

0 comments
0 FacebookTwitterPinterestEmail
Health

Major new study says intermittent fasting may not work for weight loss

by Chief Editor
written by Chief Editor

Intermittent Fasting’s Fall From Grace: What Does the Latest Research Mean for Your Diet?

For years, intermittent fasting (IF) has been hailed as a revolutionary approach to weight loss and overall health. From social media influencers to celebrities, the buzz around IF has been deafening. But a major new review is challenging that narrative, suggesting that this popular dieting trend may be no more effective than traditional dietary advice – or even doing nothing at all.

The Cochrane Review: A Reality Check

A comprehensive analysis by Cochrane, a globally recognized organization dedicated to high-quality health research, examined 22 randomized clinical trials involving nearly 2,000 adults across North America, Europe, China, Australia, and South America. The findings, published in February 2026, revealed “little to no difference” in weight loss between those practicing intermittent fasting and those following standard dietary recommendations. The results were, according to researchers, barely more effective than taking no action at all.

“Intermittent fasting just doesn’t seem to work for overweight or obese adults trying to lose weight,” stated Dr. Luis Garegnani, lead researcher and director of the Universidad Hospital Italiano de Buenos Aires Cochrane Associate Center. While acknowledging it might suit some individuals, he emphasized that the current evidence doesn’t support the widespread enthusiasm seen on social media.

Why the Disconnect Between Hype and Reality?

The surge in IF’s popularity is largely fueled by its perceived simplicity and promises of rapid results. Common methods include limiting meals to an eight-hour window or fasting every other day. However, the Cochrane review suggests these methods don’t translate into significant weight loss for most people.

Experts suggest that the focus on *when* you eat may be overshadowing the importance of *what* you eat. Dr. Gillian Goddard, a New York-based endocrinologist, noted that all diets are simply tools, and finding one that fits long-term is crucial.

Beyond Weight Loss: What About Other Benefits?

While the review focused primarily on weight loss, the potential benefits of intermittent fasting extend beyond the scale. Some studies have suggested positive effects on blood sugar control and metabolic health, particularly for individuals with Type 2 diabetes. However, the Cochrane review didn’t delve deeply into these areas, highlighting a gap in current research.

The review also noted limitations in the existing research. Most studies were relatively short-term (12 months or less), lacked diverse participant groups (primarily White adults from high-income countries), and didn’t consistently report on participant satisfaction or long-term health outcomes.

What Does This Mean for Your Diet?

The findings don’t necessarily mean intermittent fasting is “subpar,” but they do suggest it’s not a magic bullet. Sustainability is key to long-term weight management. Experts recommend focusing on balanced eating plans like the Mediterranean diet or the DASH diet, which have a strong evidence base supporting their health benefits.

“If someone really wants to try intermittent fasting, I would suggest that they try it for a few weeks, but then gradually transition to a more sustainable plan that promotes healthy eating,” advised a health expert.

Pro Tip: Focus on whole, unprocessed foods, regardless of your eating pattern. Prioritize protein, healthy fats, and complex carbohydrates for sustained energy and satiety.

FAQ: Intermittent Fasting and the Latest Research

  • Is intermittent fasting completely ineffective? Not necessarily. It may work for some individuals, but the evidence doesn’t support widespread recommendations for weight loss.
  • What diets are more effective for weight loss? Balanced eating plans like the Mediterranean diet and the DASH diet have a strong evidence base.
  • Are there any benefits to intermittent fasting beyond weight loss? Some studies suggest potential benefits for blood sugar control, but more research is needed.
  • What should I consider before trying intermittent fasting? Talk to your doctor, especially if you have underlying health conditions.

As obesity rates continue to climb worldwide, with over 2.5 billion adults overweight in 2022, finding effective and sustainable weight-loss strategies remains a critical public health challenge. The latest research on intermittent fasting serves as a reminder that there’s no one-size-fits-all solution, and a personalized approach to diet and lifestyle is often the most successful.

Explore more lifestyle stories on Fox News.

0 comments
0 FacebookTwitterPinterestEmail
Tech

Nestle Health Science, Australian Catholic University set up start-up incubator

by Chief Editor
written by Chief Editor

Nutrition’s Next Wave: How Start-ups and Science are Tackling Women’s Health, Longevity & GLP-1 Challenges

A latest incubator program, born from a partnership between the Australian Catholic University (ACU) and Nestlé Health Science, is poised to accelerate innovation in the nutrition sector. The initiative, focused on women’s health, healthy longevity, and weight management, aims to bridge the gap between cutting-edge research and real-world solutions.

Fueling Innovation: The ACU-Nestlé Incubator Model

The ACU incubator will provide start-ups with access to university research facilities and industry mentorship, fostering a collaborative environment where ideas can scale. Start-ups will pitch nutrition-focused innovations, including those incorporating lifestyle adjustments. This isn’t about creating finished products, but rather supporting the journey from concept to deployment. Nestlé Health Science is too supporting similar programs with Tufts University and the University of California, Davis, demonstrating a global commitment to nurturing the next generation of health science leaders.

Why These Three Areas? A Holistic Approach to Wellbeing

Professor Leonidas Karagounis of ACU’s Mary MacKillop Institute for Health Research, who leads the incubator, explains the interconnectedness of the chosen focus areas. “These three areas have been chosen because they are all interlinked,” he says. Metabolic dysfunction, muscle weakness, and chronic inflammation are all factors that play a role in cellular aging and overall health. The program will specifically address nutritional needs during perimenopause, an area where research has historically been lacking.

The GLP-1 Revolution and the Need for Nutritional Support

One key area of exploration will be innovations surrounding GLP-1 medications for weight management. While these drugs are effective in reducing appetite, they can also lead to undernutrition if not carefully managed. The incubator will investigate nutritional interventions to complement these medications, ensuring users receive adequate micronutrients and overall nourishment. Researchers are also exploring nutraceuticals as alternatives for those who prefer not to use pharmaceutical interventions.

“The advent of GLP targeted medications…may result in undernutrition…due to reductions in appetite,” explains Professor Karagounis. “What we are trying to do is understand how, and identify nutritional interventions that can complement such pharmaceutical interventions.”

Beyond Protein: Optimizing Muscle Health During Weight Loss

While increased protein intake is often recommended to mitigate muscle loss during weight loss, researchers are looking beyond simple supplementation. High protein levels can increase satiety, potentially reducing overall nutrient intake. The focus is shifting towards a more holistic approach, considering lifestyle adjustments and long-term sustainability, even after individuals discontinue GLP-1 medications.

“Ingestion of high protein levels alone is not the solution to maintaining muscle mass during weightloss,” Professor Karagounis emphasizes.

Precision Nutrition: Leveraging Cutting-Edge Technology

ACU’s investment in a state-of-the-art human metabolic chamber – the first of its kind in the Southern Hemisphere – will be crucial for advancing precision nutrition research. This technology allows for real-time, continuous monitoring of energy expenditure and substrate utilization, enabling researchers to develop personalized nutritional recommendations based on individual lifestyles.

“We want to develop solutions in precision nutrition based on a person’s lifestyle by performing real-time and continuous free living assessments…in our state-of-the-art human metabolic chamber,” says Professor Karagounis.

The Future of Nutrition: A Focus on Cellular Health

Research is also exploring the role of autophagy – a cellular “clean-up” process – in healthy aging. Can specific food components stimulate autophagy, potentially enhancing cellular health and longevity? This is just one example of the innovative questions the incubator aims to address.

Frequently Asked Questions

  • What is the goal of the ACU-Nestlé incubator? To help start-ups develop and deploy innovative nutrition solutions.
  • What are the three key focus areas? Women’s health, healthy longevity, and weight management.
  • Will the incubator provide funding to start-ups? No, the program focuses on providing access to expertise, research facilities, and mentorship.
  • Is this partnership unique to ACU? No, Nestlé Health Science is supporting similar initiatives at Tufts University and the University of California, Davis.

Pro Tip: Staying informed about emerging research in nutrition and lifestyle medicine is key to optimizing your health and wellbeing. Look for evidence-based information from reputable sources.

What are your thoughts on the future of nutrition? Share your comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

‘What no one tells you about life after Ozempic’: Nutritionist shares what happens after you stop using weight loss drug

by Chief Editor
written by Chief Editor

The Ozempic Plateau: What Happens When the Weight Loss Stops?

Drugs like Ozempic, Wegovy, and Mounjaro have become household names, initially for managing type 2 diabetes but increasingly for their weight loss effects. However, a growing conversation is emerging – what happens after you stop taking these medications? The initial weight changes are considered a secondary effect, and experts are now highlighting the challenges individuals face when discontinuing use.

The Return of Hunger and Anxiety

Chelsey Buckley, a certified nutrition coach, has brought attention to the often-unspoken realities of life after Ozempic. She emphasizes that stopping the medication can trigger a resurgence of hunger and anxiety surrounding food. This isn’t a sign of personal weakness, but rather a consequence of not learning how to sustainably fuel the body without pharmaceutical assistance.

Fear of Regain: A Common Struggle

Buckley notes that a significant fear for many is regaining the weight they worked so hard to lose. This fear can lead to restrictive eating patterns, overthinking every bite, and a return to the mindset that initially prompted them to seek medication. It’s a cycle that can be difficult to break without proper support.

Rebuilding Your Metabolism: The Real Work Begins

The most crucial point, according to Buckley, is that stopping Ozempic isn’t the finish line – it’s where the real work begins. It’s not about minimizing calorie intake; it’s about rebuilding a healthy metabolism, restoring muscle mass, and re-establishing a trusting relationship with food. This requires a shift in focus from restrictive dieting to sustainable lifestyle changes.

Beyond the Initial Weight Loss: A Growing Trend

The discussion around Ozempic and similar drugs extends beyond initial weight loss. A recent study involving 60,000 people worldwide is investigating potential benefits beyond weight management, including a possible reduction in dementia risk and curbing nicotine cravings. Semaglutide (the active ingredient in Ozempic and Wegovy) is TGA approved for both type 2 diabetes and chronic weight management.

The Off-Label Use and Public Interest

Interest in the off-label use of Ozempic and Wegovy has been significant, prompting research into its broader effects. However, reports and experts are also raising concerns about potential health side effects, particularly after discontinuing the drug.

Navigating Life After Medication: Seeking Support

Buckley stresses the importance of seeking support and a personalized plan when coming off Ozempic. She emphasizes that a modern diet isn’t necessarily the answer; instead, individuals need guidance and a sustainable approach to long-term health.

Did you know?

Metformin, another medication sometimes used for weight management, has caused adverse reactions in some individuals, leading them to discontinue use, as noted in a Facebook post from January 31, 2025.

FAQ: Life After Ozempic

Q: Is it normal to experience anxious about food after stopping Ozempic?
A: Yes, anxiety and confusion around food are common experiences, as the medication previously regulated appetite and digestion.

Q: What should I focus on after stopping Ozempic?
A: Rebuilding your metabolism, restoring muscle mass, and developing a healthy relationship with food are key.

Q: Do I need to follow a strict diet after stopping Ozempic?
A: Not necessarily. Focus on sustainable lifestyle changes and fueling your body appropriately, rather than restrictive dieting.

Q: Where can I identify support for stopping Ozempic?
A: Consider working with a certified nutrition coach or healthcare professional to develop a personalized plan.

Pro Tip: Prioritize whole, unprocessed foods to support metabolic health and rebuild your relationship with food.

Have you experienced challenges after stopping Ozempic or a similar medication? Share your thoughts in the comments below!

Explore more articles on healthy eating and weight management to learn more about sustainable lifestyle changes.

0 comments
0 FacebookTwitterPinterestEmail
Health

Novo Nordisk’s New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?

by Chief Editor
written by Chief Editor

Novo Nordisk’s Next Act: Can CagriSema Reclaim GLP-1 Dominance?

Ozempic has been a major growth driver for Novo Nordisk (NYSE: NVO) for years, becoming a household name in the process. However, the Danish drugmaker has recently lost ground to Eli Lilly (NYSE: LLY) in the competitive GLP-1 market. Can Novo Nordisk regain its footing? The answer likely lies in its next-generation therapies, as current product sales are expected to decline this year, according to company guidance.

Introducing CagriSema: A Dual-Action Approach

One of Novo Nordisk’s most promising candidates is CagriSema. This investigational medicine has been gaining attention for its potential to outperform existing GLP-1 drugs. CagriSema is a dual agonist, mimicking the actions of both GLP-1 and amylin – gut hormones that regulate blood sugar and appetite.

Phase 3 Trial Results: CagriSema vs. Semaglutide

Late in 2024, Novo Nordisk announced positive results from a phase 3 weight-loss clinical trial. CagriSema demonstrated superior performance compared to semaglutide (Wegovy for weight loss and Ozempic for diabetes) in overweight or obese patients without type 2 diabetes. After 68 weeks, CagriSema led to a mean weight reduction of 22.7%, compared to 16.1% with Wegovy.

Patient self-administering shot.

CagriSema in Type 2 Diabetes: Another Victory

Novo Nordisk recently shared data from another late-stage study, this time comparing CagriSema to Ozempic in patients with type 2 diabetes who were also overweight or obese. CagriSema resulted in an average 1.91% reduction in blood sugar from baseline (8.2%) and an average weight loss of 14.2%. Again, CagriSema outperformed Ozempic in this trial.

What’s on the Horizon for Novo Nordisk?

Novo Nordisk has already submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for its use in diabetes after completing two additional phase 3 studies, including one focused on cardiovascular outcomes. Wegovy has also recently received label expansions, including for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), which is expected to boost sales.

Manufacturing Challenges and Competition

Despite CagriSema’s promising results, manufacturing complexities and potential costs are concerns. It is expected to be more difficult and expensive to produce than semaglutide, which has previously faced supply constraints. Eli Lilly’s retatrutide, which demonstrated a mean weight loss of up to 28.7% in a phase 3 study, presents a strong competitive challenge.

Is Novo Nordisk a Good Investment?

While Eli Lilly currently appears poised to maintain its lead in the anti-obesity drug market, CagriSema’s superiority to Wegovy and Ozempic should help Novo Nordisk improve its performance, particularly as the company expands its manufacturing capacity. Novo Nordisk also has several other promising diabetes and weight management products in development, including Amycretin, in both oral and subcutaneous formulations.

Frequently Asked Questions (FAQ)

What is CagriSema?
CagriSema is an investigational medicine from Novo Nordisk that mimics the actions of two gut hormones, GLP-1 and amylin, to help regulate blood sugar and appetite.
How does CagriSema compare to Wegovy?
In a phase 3 trial, CagriSema led to a greater mean weight reduction (22.7%) than Wegovy (16.1%) after 68 weeks.
What are the potential challenges for Novo Nordisk?
Manufacturing complexities, higher production costs, and competition from Eli Lilly’s retatrutide are potential challenges.

Don’t miss out! Our analyst team has identified the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. Discover the stocks that could deliver significant returns in the years ahead!

See the 10 stocks »

*Stock Advisor returns as of February 16, 2026.

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts